BioSpace News Archive

Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) today announced financial results for the fourth quarter and full year of 2023 and associated Company developments.

Progyny, Inc. (Nasdaq: PGNY) (“Progyny” or the “Company”) today announced its financial results for the three- and twelve-month periods ended December 31, 2023 (“the fourth quarter of 2023” and “the full year”, respectively) as compared to the three- and twelve-month periods December 31, 2022 (“the fourth quarter of 2022” and “the prior year period”, respectively).

OraSure Technologies, Inc., a leader in point-of-care and home diagnostic tests, sample management solutions, and microbiome laboratory and analytical services, announced its financial results for the three months ended December 31, 2023.

Tyra Biosciences, Inc., a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor biology, announced that company management will participate in the following investor conferences.

Cumberland Pharmaceuticals Inc., a specialty pharmaceuticals company, announced that it will release its annual 2023 financial results and provide a company update after the market closes on Tuesday, March 5, 2024.

China Jo-Jo Drugstores, Inc., a Cayman Islands exempted company, reported that it expects to implement a 1-for-20 reverse stock split on its ordinary shares effective Friday, March 1, 2024, with trading to begin on a split-adjusted basis at the market open on that day.

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided a review of recent business and clinical highlights.

Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that management will participate in a targeted oncology panel at the TD Cowen 44th Annual Health Care Conference, taking place March 4-6, 2024, in Boston, MA.

CytomX Therapeutics, Inc. today announced that management will participate in the following investor conferences in March.

Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY0) (“Clearmind” or the “company”) announced that it has submitted three additional patent applications under the international Patent Cooperation Treaty (“PCT”), as part of its ongoing collaboration with SciSparc Ltd. (Nasdaq: SPRC) (“SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system.